STK11

Serine/threonine-protein kinase STK11 · Q15831 · STK11 on Sugi Atlas →

1,838 patent compounds predicted against STK11, 1,169 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Azd-1480 (SCHEMBL219103)	1.00	1/20
Azd-1480 (SCHEMBL220400)	1.00	1/20
Pacritinib (SCHEMBL1108221)	1.00	1/20
Azd-1480 (SCHEMBL3345019)	1.00	1/20
Dinaciclib (SCHEMBL12048446)	1.00	1/20
Pacritinib (SCHEMBL2537450)	0.98	1/20
SCHEMBL1108252	0.92	1/20
Pacritinib (SCHEMBL2485104)	0.89	1/20
SCHEMBL12048531	0.83	1/20
Pacritinib (SCHEMBL2336009)	0.83	1/20
SCHEMBL1108239	0.83	1/20
SCHEMBL1108263	0.81	1/20
SCHEMBL1108265	0.81	1/20
SCHEMBL12953008	0.81	1/20
SCHEMBL12953146	0.81	1/20
SCHEMBL12953641	0.81	1/20
SCHEMBL12954295	0.81	1/20
SCHEMBL13116917	0.81	1/20
SCHEMBL217992	0.80	1/20
SCHEMBL218888	0.80	1/20

Clinical trials — most relevant to STK11 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER	PHASE2/PHASE3	RECRUITING
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations	PHASE2	COMPLETED
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)	PHASE2	COMPLETED
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.	PHASE2	ACTIVE_NOT_RECRUITING
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours	PHASE2	ACTIVE_NOT_RECRUITING
Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma	PHASE2	UNKNOWN
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies	PHASE1/PHASE2	RECRUITING
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma	PHASE2	UNKNOWN
Study of ASTX029 in Subjects With Advanced Solid Tumors	PHASE1/PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation	PHASE1/PHASE2	RECRUITING
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors	PHASE1/PHASE2	NOT_YET_RECRUITING
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects	PHASE1/PHASE2	COMPLETED
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors	PHASE1	RECRUITING
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).	PHASE1	ACTIVE_NOT_RECRUITING
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)	PHASE1	COMPLETED
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.	PHASE1	ACTIVE_NOT_RECRUITING
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors	PHASE1	RECRUITING
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy	PHASE1	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Pancreatic Cancer Early Detection Consortium	nan	RECRUITING
Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals	nan	RECRUITING
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Exercise in Type 1 Diabetes Mellitus	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a STK11 binder may also engage these)

Protein	Name	Similarity
Q0GGW5	—	1.000	Q0GGW5 →
Q9WTK7	—	0.998	Q9WTK7 →
D4AE59	—	0.996	D4AE59 →
Q91604	—	0.991	Q91604 →
P49138	—	0.953	P49138 →
Q9Y6N9	—	0.952	Q9Y6N9 →
MAPKAPK3	MAP kinase-activated protein kinase 3	0.952	landscape →
Q3MHQ0	—	0.951	Q3MHQ0 →
Q66H84	—	0.951	Q66H84 →
MAPKAPK2	MAP kinase-activated protein kinase 2	0.949	landscape →
Q3SYZ2	—	0.949	Q3SYZ2 →
Q5XIS9	—	0.947	Q5XIS9 →
B1H3E1	—	0.946	B1H3E1 →
Q91987	—	0.945	Q91987 →
P24786	—	0.944	P24786 →
NTRK3	NT-3 growth factor receptor	0.943	landscape →
Q8QGV6	—	0.943	Q8QGV6 →
Q5IS37	—	0.943	Q5IS37 →
A0A8I5ZNK2	—	0.943	A0A8I5ZNK2 →
Q3UMW7	—	0.943	Q3UMW7 →
P50904	—	0.942	P50904 →
Q5IFJ9	—	0.942	Q5IFJ9 →
Q01887	—	0.942	Q01887 →
PRKD2	Serine/threonine-protein kinase D2	0.942	landscape →
Q03351	—	0.942	Q03351 →
NEK10	Serine/threonine-protein kinase Nek10	0.941	landscape →
Q8BZ03	—	0.941	Q8BZ03 →
O88506	—	0.940	O88506 →
Q6P9R2	—	0.940	Q6P9R2 →
Q5IS82	—	0.940	Q5IS82 →